Safe, effective, short-term glucose control seen in MK-0941 users

12/1/2011 | PhysiciansBriefing.com

Type 2 diabetes patients on stable-dose insulin glargine who used the glucokinase inhibitor MK-0941 had better A1C and two-hour post-meal glucose levels at week 14, compared with those who took a placebo, according to a study in Diabetes Care. However, researchers found that such improvements in glycemic control were not sustained by 30 weeks.

View Full Article in:

PhysiciansBriefing.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY